In our subgroup analysis, compared with chemotherapy, a significantly overall survival benefit was only observed for specific patients with brain metastases (ie, immune monotherapy, non-small-cell lung cancer, median follow-up > 20 months, and targeting PD-L1) treated with ICIs. This evidence concerns the gene CD274 and non-small cell lung carcinoma.